The New York City-based Memorial Sloan Kettering Cancer Center has launched an Innovation Hub (iHub), designed to provide a focused avenue for healthcare innovators to partner with MSK to accelerate the development of their products and business.
From startups to leading global corporations, partners are essential to the iHub’s mission to lead the world in shaping the future of cancer care and prevention, leaders of the organization contend. To deliver on that mission, MSK has selected the following investment areas for this year:
- Digital therapeutics - digital solutions that deliver evidence-based therapeutic interventions to prevent, manage, or treat cancer-related healthcare conditions, with a focus on prevention, screening, adherence, pain management and mental health
- AI enabled computational oncology – solutions that use computational models to improve tumor classification and treatment planning, define tumor progression, and identify predictive biomarkers using a combination of genomic, clinical, and radiological data
- Population insights - solutions for early detection and diagnosis, screening, risk stratification, and high-risk surveillance and monitoring, using relevant clinical, genomic and environmental data
- Remote patient monitoring - technologies that enable patient monitoring outside of conventional care settings to manage, evaluate, notify, and modify treatment plans
MSK officials note that the organization works closely with its partners to accelerate the development and commercialization of innovative healthcare solutions in exchange for a stake in the commercialization outcome. iHub collaborations are anchored on the partner company’s product/IP, where MSK may provide iHub partners with unique acceleration capabilities including:
- Clinical intelligence: Inform product design and development, as well as clinical study design, by working with leading subject matter experts
- Market intelligence: Access to MSK leadership teams and their unique knowledge of healthcare industry
- Product development: Leverage select MSK resources to support product development and commercialization, including generating meaningful data and evidence for solutions through clinical studies
- Marketing: Support go-to-market strategy
To apply to the MSK iHub, candidates can fill out the initial application form. Solutions that are most relevant to the investment areas will be asked to fill out the full application form, which will be reviewed by the MSK leadership team, and select industry experts. The initial form opens to the public on Oct. 15, and by Nov. 13, the MSK iHub leadership team will select candidates to move on to full application stage.
